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In the last decade, more and more oncology centers are challenged with complementary medicine (CM)
integration within supportive breast cancer care. Quality of life (QOL) improvement and attenuation of oncology
treatment side effects are the core objectives of integrative CM programs in cancer care. Yet, limited research is
available on the use of specific CM modalities in an integrative setting and on cancer patients’ compliance with CM
consultation. Studies are especially warranted to view the clinical application of researched CM modalities, such as
anthroposophic medicine (AM), a unique CM modality oriented to cancer supportive care. Our objective was to
characterize consultation patterns provided by physicians trained in CM following oncology health-care
practitioners’ referral of patients receiving chemotherapy. We aimed to identify characteristics of patients who
consulted with AM and to explore patients’ compliance to AM treatment. Of the 341 patients consulted with
integrative physicians, 138 were diagnosed with breast cancer. Following integrative physician consultation, 56
patients were advised about AM treatment and 285 about other CM modalities. Logistic multivariate regression
model found that, compared with patients receiving non-anthroposophic CM, the AM group had significantly
greater rates of previous CM use [EXP(B) = 3.25, 95% C.I. 1.64-6.29, p = 0.001] and higher rates of cancer recurrence
at baseline (p = 0.038). Most AM users (71.4%) used a single AM modality, such as mistletoe (viscum album)
injections, oral AM supplements, or music therapy. Compliance with AM modalities following physician
recommendation ranged from 44% to 71% of patients. We conclude that AM treatment provided within the
integrative oncology setting is feasible based on compliance assessment. Other studies are warranted to explore
the effectiveness of AM in improving patients’ QOL during chemotherapy.
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Integrating complementary medicine (CM) within can-
cer supportive care is an increasing phenomenon in con-
ventional cancer institutions across the globe (Ben-Arye
et al. 2013). Anthroposophic medicine (AM) was one of
the first CM modalities integrated within conventional
oncology care settings and is mostly well-known due to
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in any medium, provided the original work is pin in vitro and clinical studies (Kienle 2006; Horneber
et al. 2008; Lev et al. 2011). In a systematic review,
Kienle et al. found that quality of life (QOL) and toler-
ability of chemotherapy, radiotherapy or surgery were
improved in patients receiving mistletoe in 21 of 24 clinical
studies (15 randomized, 9 non-randomized) conducted
with breast and gynecological cancer patients (Kienle et al.
2009). In the arena of basic science breast cancer research,
mistletoe effects included prevention of surgery-induced
suppression of granulocyte function (Büssing et al. 2005),
DNA repair in damaged peripheral blood mononuclear
cells (Kovacs 2002), cytotoxic effect (Martín-Cordero et al.
2001), and effects in different breast cancer cell lines
on immune defense and stress response genes, as wells an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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(Eggenschwiler et al. 2006).
Anthroposophic medical care is based on collaborative
teamwork of physicians, nurses, art therapists, physical/
massage therapists, psychotherapy and biography coun-
seling, and more. AM practitioners perceive spiritual ele-
ments in the healing process and target treatment to
strengthen the organism by stimulation of self-healing
(Kienle et al. 2006). AM modalities in cancer care may in-
clude nutritional, herbal (including mistletoe treatment),
homeopathic and herbal remedies as well as referral to
anthroposophic practitioners (e.g. music therapists).
In this study, we explore the use of anthroposophic
medicine in a setting where AM is provided as part of
an Integrative Oncology Program (IOP) operating within
a conventional oncology service of the largest health
maintenance organization in northern Israel. The inclu-
sion of the IOP within the oncology service supportive
care was launched in 2008, aiming at improving patients’
quality of life during chemotherapy and advanced dis-
ease states (Ben-Arye et al. 2012a). The study of AM
provided in this setting is unique since referral to CM
consultation is determined by oncology health care pro-
viders (HCPs include oncologists, nurses, social workers)
on a free-of-charge basis while outcomes are monitored
using a research-based registry protocol. Our study objec-
tives were to identify characteristics of patients receiving
AM compared to non-AM complementary therapies, to
explore clinical indications for the use of AM-based treat-
ments, and to evaluate compliance with AM treatments in
this setting.
Materials and methods
Study sites and participants
The study took place at two oncology centers operated
by Clalit Health Services in northern Israel between July
2009 and January 2013. These oncology services provide
conventional oncology treatment to more than 1000 new
patients each year.
Registry protocol data collection
The clinical activities of the integrative oncology pro-
gram (IOP) are documented in a research-based registry
protocol. Referral to the IOP may be initiated by the pa-
tient’s oncologist, oncology nurse or social worker, and
is limited to patients treated within the oncology service
during chemotherapy and/or advanced cancer. Following
the referral, an initial integrative medical intake inter-
view was scheduled with an integrative physician (IP)
who is a medical doctor with extensive training in the
field of CM (including AM). The IP interview lasted ap-
proximately an hour, and addressed the patient’s past ex-
perience and present expectations regarding the use of
CM. Each session typically concluded with an outliningof treatment goals, followed by the construction of a
preliminary treatment plan tailored to the patient’s out-
look and level of evidence (efficacy, safety, possible inter-
actions with chemotherapy, etc.). The CM treatment
plan was provided by the IPs or CM practitioners and
may have included herbal/dietary supplements and nu-
tritional consultation; acupuncture and manual modal-
ities; anthroposophic medicine; and mind-body therapies
(e.g. guided imagery, music therapy, and spiritual coun-
seling). The frequency of CM treatments ranged from
once a week to once every three weeks. Following
2–4 months of treatment, a concluding clinical assess-
ment was performed.
Data analysis
Data were evaluated using the SPSS software program
(version 18; SPSS Inc., Chicago, IL). Pearson’s chi-square
test and Fisher’s exact test were used to detect differ-
ences in the prevalence of categorical variables and
demographic data between the participants in various
groups. In addition, a t-test was performed to determine
any differences in the continuous variables when nor-
mality was assumed. In cases of non-normal distribution,
the Mann–Whitney U test was used. A logistic multi-
variate regression model was developed to assess the fac-
tors associated with patients receiving AM treatments
versus those receiving other CM modalities. The regres-
sion model included patients’ age, gender, language
(identifying Hebrew, Arabic and Russian-speaking par-
ticipants), use of CM for cancer-related outcomes or for
general non-cancer-related reasons, and prevalence of
cancer recurrence. A p value of ≤0.05 was considered to
be of statistical significance.
Ethical considerations
Prior to initiation of the study, approval was received
from the Ethics (Helsinki) Committee at the Carmel
Medical Center, Haifa, Israel. Participation in the study
was voluntary, and information was collated in an an-
onymous fashion, after the patient signed an informed
consent.
Results and discussion
During the study period, 341 patients received con-
sultation by the IP following an HCP referral. All the
participating patients were undergoing either active
chemotherapy, palliative treatment, or both. Table 1
compares demographics, treatments, and cancer-related
variables between patients who consulted to receive an
AM-based CM treatment regimen (AM group; n = 56,
16.4%) and those who consulted with no AM CM treat-
ment regimen (non-AM group; n = 285, 83.6%). The most
frequent cancers were breast (138 patients, 41.8%), gastro-
intestinal (78, 23.6%), and gynecological (65, 19.7%).
Table 1 Comparison of demographic, treatment, and cancer-related variables between AM- recommended treatment
regimen patients and non-AM recommended treatment regimen patients
Characteristic Total cohort N = 341,
n (%)
AM group N = 56,
n (%)
Non-AM group N = 285,
n (%)
P value
Age [Mean in years ± SD (median)] 62.26 ± 12.58 (63) 64.05 ± 11.55 (64.5) 61.91 ± 12.77 (63) 0.24
Sex
Male 84 (24.6) 12 (21.4) 72 (25.3) 0.63
Female 257 (75.4) 44 (78.6) 213 (74.7)
Main language*:
Hebrew 243 (73.4) 47 (85.5) 196 (71.0) Hebrew vs. non-Hebrew
Arabic 32 (9.7) 3 (5.5) 29 (10.50)
Russian 56 (16.9) 5 (9.1) P = 0.029
Country of birth*
Israel 157 (48.2) 28 (52.8) 129 (47.3) Israeli-born vs. others
Europe/America 84 (25.8) 13 (24.5) 71 (26.0)
Asia/Africa 30 (9.2) 6 (11.3) 24 (8.8) P = 0.55
Former USSR 55 (16.9) 6 (11.3) 49 (17.9)
Residence distance*
Haifa** 134 (39.3) 21 (37.5) 113 (39.6) 0.88
Suburbs** 130 (38.1) 21 (37.5) 109 (38.2)
Periphery** 77 (22.6) 14 (25.0) 63 (22.1)
Cancer sites*
Breast 138 (41.8) 24 (44.4%) 114 (41.3%) 0.76
Gynecological 65 (19.7%) 13 (24.1%) 52 (18.8%) 0.36
Gastrointestinal 78 (23.6%) 10 (18.5%) 68 (24.6%) 1.00
Prostate + urologic 31 (9.4%) 5 (9.3%) 26 (9.4%) 0.38
Lung 18 (5.5%) 2 (3.7%) 16 (5.8%) 0.74
Cancer recurrence*
Recurrent 82 (24.0) 19 (33.9) 63 (22.1) 0.062
Non-recurrent 259 (76.0) 37 (66.1) 222 (77.9)
Evidence for advanced cancer*
Metastases 159 (46.6) 28 (50.0) 131 (46.0) 0.66
Non-metastatic 182 (53.4) 28 (50.0) 154 (54.0)
Chemotherapy setting*
Neoadjuvant + adjuvant 209 (65.7) 34 (61.8) 175 (66.5) 0.53
Palliative + Curative 109 (34.3) 21 (38.2) 88 (33.5)
Non-cancer related CM use*
Users 165 (48.5) 42 (75.0) 123 (43.3) <0.0001
Non-users 175 (51.5) 14 (25.0) 161 (56.7)
Cancer-related CM use*
Users 170 (50.1) 39 (69.9) 131 (46.3) 0.002
Non-users 169 (49.9) 17 (30.4) 152 (53.7)
Notes:
SD standard deviation; Data analysis was performed by t-test, Fisher’s exact test, and Pearson Chi-square test.
*Data is limited to the number of respondents who reported this information.
**In relation to residential distance from Haifa: suburbs – up to 20 km from Haifa; periphery –beyond 20 km from Haifa.
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groups with respect to age, gender, country of birth, dis-
tance of residence from the oncology center, extent of
cancer involvement (local vs. metastatic disease), recur-
rence, and chemotherapy setting (e.g., neo-adjuvant and
adjuvant vs. palliative). Nevertheless, patients receiving
AM were predominantly Hebrew speakers (p = 0.014,
compared with Arabic and Russian) and used CM sig-
nificantly more for general (p < 0.0001) or cancer-related
outcomes (p = 0.002) prior to the IP consultation.
Factors predicting anthroposophic medicine consultation
A logistic multivariate regression model was conducted to
assess the independency of the above variables. An AM-
based treatment regimen was associated with previous CM
use [EXP(B) = 3.25, 95% C.I. 1.64-6.29, p = 0.001], CM use
for cancer-related outcomes [EXP(B) = 2.34, 95% C.I. 1.21-
4.51, p = 0.011], cancer recurrence [EXP(B) = 2.03, 95% C.I.
1.03-3.98, p = 0.038], and Hebrew speakers [EXP(B) = 2.96,
95% C.I. 1.28-6.79, p = 0.011].
Treatment goals of AM and non-AM treatment regimens
Figure 1 shows that integrative physicians had similar treat-
ment goals for patients recommended to AM or non-AM
treatments. Leading treatment goals were (in decreasing
order) fatigue improvement (75–78.6% of patients), ameli-
oration of gastrointestinal concerns (60.7-67.9%; e.g., sto-
matitis, nausea, constipation, diarrhea, weight & appetite
change), alleviation of emotional distress (48.9-55.4%), and
pain and neuropathy management (33.9-38.9%).
AM modalities use: clinical indications and compliance
In Table 2, we present three AM medicine modalities pre-
scribed for quality of life (QOL) improvement: MistletoeFigure 1 Integrative treatment goals (% of patients in each group).(Viscum album) injections, AM supplements, and AM
music therapy. Forty of the 56 AM users (71.4%) used only
one of these three modalities and 16 (28.6%) used com-
bined AM therapies. Common clinical indications for AM
use and specific AM supplements used are specified in
Table 2.
Compliance with AM treatments was assessed by
comparing IP recommendations in the initial visit to
the report in the concluding clinical assessment following
2–4 months of treatment. Of the three AM modalities,
AM supplement use had the highest patient compliance
rate (71.4%) followed by mistletoe injections (52.2%) and
optimal music therapy sequence of more than three ses-
sions (44%). Overall, 40 of the 56 patients in the AM
group complied with at least one of the three AM therap-
ies (71.4%).
Discussion
This study focuses on the characteristics of AM use pro-
vided within a unique setting of CM consultation and
treatment integrated within a conventional public oncol-
ogy service in the largest HMO in Israel. Although CM
use by people with cancer in Israel is highly prevalent
(about 50% of patients during chemotherapy) (Ben-Arye
et al. 2012b; Ben-Arye et al. 2006), the use of AM is lim-
ited by the following potential reasons: lack of AM
coverage in the Israeli national medical insurance plans,
unfamiliarity with AM philosophy and practice, reluc-
tance to inject mistletoe subcutaneously, and limited ac-
cessibility to physicians and non-physician practitioners
who practice AM. In our study, some of these potential
limitations were reduced due to a built-in referral process
by an IP and practitioners who have received exten-
sive training in AM. The construction of the integrative
Table 2 Clinical indications of 3 anthroposophic medicine modalities prescribed for quality of life (QOL) improvement
AM modality Number of AM users Common QOL-oriented clinical indications
(including specific supplements indicated)
Patient compliance
n (%) n (%)





AM supplements 28 (50.0) Fatigue (Levico D1 or Levico comp D3) 20 (71.4)*
Chemotherapy-induced
neuropathy (Aconite nervenoil)
Insomnia (Soleum uleginosum; Avena sativa comp, Hepatodoron)









* Documented use in medical file.
** Up to 3 sessions.
***More than 3 sessions.
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variety of factors: a) the spectrum of patients’ concerns,
symptoms, and well-being; b) level of research supporting
CM modality efficacy and safety (including interactions
with chemotherapy) in specific oncology settings (cancer
site, stage, and treatment protocol); c) patient readiness to
experience different CM modalities. This patient-centered
design may be considered as a major bias in determining
referral to AM rather than non-AM integrative treat-
ments. Nevertheless, our methodology research of a
non-randomized preference study tailored to patients’
needs and concerns can be also perceived as a real-world
pragmatic trial.
One of the major findings in our study is that patients
in the AM group had higher rates of cancer recurrence
compared with patients receiving non-AM CM con-
sultation. This finding may suggest that AM may be
considered in our setting as a second-line of integrative
treatment compared with other CM modalities, such as
acupuncture, herbs and nutrition, that may be perceived
as more familiar or less invasive. Other factors signifi-
cantly associated with AM use, like previous CM use and
the predominance of Hebrew speakers, emphasize the
need to conduct more studies on the potential bias of
AM inclusion in integrative medicine treatment regimens
recommended by IPs. Specifically, qualitative studies arewarranted to detect patient- as well as IP-associated fac-
tors that may influence AM-oriented consultations. An-
other point to consider in future studies is whether the
paucity of AM in integrative treatment plans is also de-
termined by quality-of-life indications and the potential
of AM to improve chemotherapy side effects and pa-
tients’ symptoms. In our study, we found no statistically
significant difference in IP treatment goals between the
AM and non-AM groups regarding four leading concerns:
fatigue, gastrointestinal symptoms, emotional distress, and
pain/neuropathy. This distribution of treatment goals may
also be dependent on the status of rigorous research on
the efficacy and safety of AM in cancer supportive care.
Most mistletoe treatment for cancer studies are in the
in vitro setting (Mengs et al. 2002) or focus on survival
(Ostermann et al. 2009) rather than QOL aspects which
are more relevant in an integrative oncology setting. Cur-
rently, the spectrum of published mistletoe QOL-oriented
research is limited to studies assessing general well-
being improvement (Brandenberger et al. 2012; Eisenbraun
et al. 2011; Kienle & Kiene 2010; Semiglazov et al. 2006;
Piao et al. 2004). Studies on specific symptom improve-
ment include leukopenia and diarrhea in gastric cancer
patients (Kim et al. 2012), reducing malignant ascites
(Bar-Sela et al. 2006), improving emotional concerns
in palliative care (Heusser et al. 2006), and lessening of
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juvant chemotherapy (Loewe-Mesch et al. 2008). Most
importantly, mistletoe safety aspects have also been
studied and complement the emerging data on efficacy
(Kienle et al. 2011; Augustin et al. 2005). In contrast to
this growing body of research on mistletoe efficacy and
safety, there is limited research regarding other AM
supplements and art therapies that may enhance pa-
tients’ supportive cancer care. Encouraging data on the
impact of art therapies on the QOL of cancer patients
was reported in studies with disease-free breast cancer
patients treated with multimodal therapy that included
eurythmy and painting therapy (improved sleep and
cancer-related fatigue) (Kröz et al. 2012), and in pa-
tients during chemotherapy participating in art therapy
sessions (Bar-Sela et al. 2007). As research develops in
clinical practice, we suggest that the referral of patients
to AM will also grow and enable IPs to better recom-
mend AM, based on research evidence.
In this manuscript, we do not report on the clinical
outcomes of patients in the AM and non-AM groups.
Data on these aspects will be published elsewhere. Our
intention was to focus on AM consultation patterns and
treatments within an integrative oncology setting rather
than on outcome data. In this regard, the report on
compliance to AM modalities ranging between 44% to
71% of patients should be carefully interpreted. In most
studies on compliance aspects in cancer care, researchers
examined the association between patients’ compliance
with standard treatment and CM used (Söllner et al. 2000).
To the best of our knowledge, our study is the first report
on CM compliance in an integrative oncology setting.
Although more studies are warranted on CM and cancer
patients’ compliance, preliminary insight can be achieved
through assessment of cancer patient’s compliance to
medication use. Studies regarding non-compliance and
adherence of patients with cancer to drug therapies as-
sociate non-compliance with drug side effects (letrozole
in breast cancer, 18.4% non-compliance rate) (Fontein
et al. 2012), forgetting to take medications, side effects
and misunderstanding instructions (capecitabine, 9%)
(Winterhalder et al. 2011). More studies are needed to ex-
plore the reasons for non-compliance or lack of adherence
in patients receiving AM in integrative settings. Potential
motives for AM treatment initiation and continuation ver-
sus non-compliance may encompass various domains,
such as symptom severity, clinical improvement or deteri-
oration that may be related to AM specific effects or to a
more non-specific therapeutic alliance with the AM practi-
tioner, cost considerations, and more.
Our study has potential limitations and its results
should be cautiously interpreted or generalized to other
settings of care. As stated previously, the major limita-
tion concerns with the non-controlled preference studymethodology. The pragmatic trial of patient-centered
tailoring of a treatment plan may have caused selection
bias of patients who were more compliant with AM or
have more advanced disease. Other limitations include
the culturally diverse mosaic of the cancer patient popu-
lations in north Israel that may affect patients’ affinity
towards AM due to historical and religious motives (e.g.,
religious Jewish and Muslim patients’ reluctance of an
apparently spiritual modality that may be affiliated with
Christianity, averseness of Holocaust survivors regarding
a Central European-dominant modality or attractiveness
of secular Israeli-born and immigrant patients to appar-
ently non-religious spirituality). Another study limitation
is the accessibility of patients to receive AM treatments
in two aspects: a) geographical – long residence distance
from the cancer center may have hindered AM provision
(music therapy in particular); b) financial – although IP
consultations and music therapy were provided at no
cost, mistletoe injections and other AM supplements
were purchased on an out-of-pocket basis and thus cost
considerations may have influenced treatment compli-
ance and adherence. Last but not least, we did not evalu-
ate the reasons for non-compliance and further studies
are needed to explore these aspects.
Conclusions
Anthroposophic medicine is an important modality that
can foster supportive cancer care, especially in patients
with breast cancer receiving chemotherapy. Leading clin-
ical indications for AM referral and treatment include fa-
tigue, gastrointestinal concerns, emotional concerns, pain
and neuropathy. Assessing patient compliance and adher-
ence to AM referral and treatment should be regarded as
an important monitoring procedure that advances the
learning process and attentiveness of health care providers
to the barriers and challenges of optimal integrative treat-
ment tailoring.
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